Viorel Sima / Shutterstock.com
Pharmaceutical company Eli Lilly has reported that its US revenue in 2014 dipped by 29% compared to the previous year, laying the blame on key patents, including those for Cymbalta (duloxetine hydrochloride) and Evista (raloxifene hydrochloride), expiring.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Eli Lilly, Cymbalta, Evista, patent expiries, results
